Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award

Key Terms

drug resistance medical

Drug resistance is when germs, viruses, or cancer cells change so a medicine that once controlled them no longer works, similar to how pests can become immune to a pesticide. For investors it matters because resistance can reduce a drug’s sales, derail clinical trials and approvals, shorten a product’s commercial life, and raise costs for companies racing to develop next-generation treatments, all of which affect revenue and risk.

ai-driven healthcare technical

AI-driven healthcare uses software that learns from medical records, images, and other health data to help detect disease, predict outcomes, personalize treatments, or automate routine tasks—like a smart assistant that helps clinicians work faster and make better decisions. It matters to investors because these tools can cut costs, speed drug and device development, improve patient results, and create new revenue streams, with value hinging on clinical validation, data access, and regulation.

digital therapeutics technical

Digital therapeutics are clinically proven software programs or apps designed to prevent, manage or treat medical conditions, often used alongside or instead of drugs and devices. They matter to investors because they can scale like software, require regulatory approval and payment from insurers or health systems, and thus offer potential recurring revenue, lower delivery costs and new market opportunities in healthcare — like a virtual prescription that replaces or enhances traditional treatment.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company selected for the Leaders in Drug Resistance Development award

LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as the Leaders in Drug Resistance Development 2026 - USA award recipient.

Following a merit-led research and evaluation process by GHP’s expert research and judging team, based on innovation, impact, business performance and contribution to patient outcomes, Kairos Pharma has been recognized as a leader in the research and development to combat drug resistance.

“Drug resistance can no longer be an afterthought when it comes to the treatments we provide patients, especially in cancer,” said Kairos Pharma Chief Executive Officer Dr. John Yu. “This recognition is a reminder of the importance of our work. Our efforts to flip the script on how our healthcare providers think about targeting cancer drug resistance are far from over, but we are thankful for the positive progress we’ve made to date and look forward to continuing this vital work to extend the life of already effective treatments through drug resistance targeting therapeutics.”

Launched in 2015, GHP’s Healthcare and Pharmaceutical Awards cover success stories and dedicated work across a diverse industry. Valued at over $10 trillion worldwide, the healthcare and pharmaceutical industry continues to expand, powered by advances in biotechnology, personalized medicine, AI-driven healthcare, and digital therapeutics. As the world’s health systems evolve to meet complex challenges, innovation and collaboration are reshaping the delivery, accessibility and effectiveness of care. The Healthcare & Pharmaceutical Awards 2026 shine a light on these visionaries redefining modern medicine, from life-changing treatments and diagnostic breakthroughs to patient-centered services and community health initiatives that raise the bar for excellence.

About Global Health & Pharma Magazine

Global Health & Pharma Magazine is part of AI Global Media, an internationally focused B2B digital publishing group founded in 2010. The group is committed to delivering content you can trust to every one of its readers, subscribers, clients, contributors, advertisers and visitors. Global Health & Pharma Magazine is a quarterly digital publication dedicated to the Healthcare, Pharmaceutical and Life Science industries. Each quarter Global Health & Pharma Magazine brings to its readers the need-to-know news and updates from key sectors, magnifying the work of those that are setting the pace and looking to change their respective sectors for the better. Utilizing this reach, Global Health & Pharma Magazine aims to provide support and help showcase the latest developments, most promising innovations and leading companies across the medical and health industries.

About Kairos Pharma, Ltd.

Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. For more information, visit kairospharma.com.

Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s Annual Report on Form 10-K and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws. More detailed information about the risks and uncertainties affecting KAPA is contained under the heading “Risk Factors” in Kairos Pharma’s Annual Report on Form 10-K filed with the SEC, which is available on the SEC's website at www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514648062/en/

Media and Investor Contact:

Kairos Pharma, Ltd.
Investor Relations
Email: investors@kairospharma.com

Source: Kairos Pharma, Ltd